Arcus Biosciences, Inc.RCUS
...Loading RCUS Peers...
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
577 Employees
CEO : Dr. Terry J. Rosen Ph.D.
Address : 3928 Point Eden Way, Hayward,CA, US, - 94545,
Key Excutives | Designation |
---|---|
Mr. Alexander Azoy | Vice President of Finance & Principal Accounting Officer |
Ms. Jennifer A. Jarrett M.B.A. | Chief Operating Officer |
Dr. Jonathan Yingling Ph.D. | Chief Scientific Officer |
Dr. Juan Carlos Jaen Ph.D. | Co- Founder & President |
Dr. K. Christopher Garcia Ph.D. | Co-Founder & Member of Scientific Advisory Board |
Ms. Carolyn C. Tang J.D. | General Counsel & Corporate Secretary |
Holli Kolkey | Vice President of Corporate Communications |
Dr. Terry J. Rosen Ph.D. | Co-Founder, Chairman & Chief Executive Officer |
Mr. Robert C. Goeltz II | Principal Financial Officer & Chief Financial Officer |
Dr. Dimitry S.A. Nuyten M.D., Ph.D. | Chief Medical Officer |